
Viatris (VTRS) Stock Forecast & Price Target
Viatris (VTRS) Analyst Ratings
Bulls say
Viatris is positioned for strong future growth with its extensive portfolio of legacy products and focus on key therapeutic areas. The company's merger with Upjohn and Mylan has solidified its position as one of the largest generic drug manufacturers in the world, with a strong presence in over 165 countries. Despite potential challenges and risks in the industry, Viatris's development of innovative drugs and potential for future growth make it a promising investment opportunity for analysts.
Bears say
Viatris is heavily reliant on the success of its new drugs, cenerimod and selatogrel, for future growth. However, the potential higher risk associated with these drugs, combined with a lack of a biosimilars vertical, make the company's strategy and its stock unappealing to financial analysts. While Viatris does have a diversified portfolio, with a strong focus on generics and biosimilars, its legacy products only make up 60% of sales and may not be enough to drive a richer multiple for the company's shares. Financial analysts have a neutral outlook on Viatris, noting its inexpensive valuation at an EV/2027E EBITDA of ~7x, but remaining cautious due to the unknown outcomes of the new drugs and lack of potential for a biosimilars vertical.
This aggregate rating is based on analysts' research of Viatris and is not a guaranteed prediction by Public.com or investment advice.
Viatris (VTRS) Analyst Forecast & Price Prediction
Start investing in Viatris (VTRS)
Order type
Buy in
Order amount
Est. shares
0 shares